Search

Andrew P. Lee

Examiner (ID: 4275, Phone: (571)270-1016 , Office: P/1621 )

Most Active Art Unit
1621
Art Unit(s)
1691, 1621, 1628, 1629
Total Applications
702
Issued Applications
283
Pending Applications
98
Abandoned Applications
332

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17759892 [patent_doc_number] => 20220233504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING LIDOCAINE AND MELATONIN [patent_app_type] => utility [patent_app_number] => 17/488241 [patent_app_country] => US [patent_app_date] => 2021-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488241 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/488241
PHARMACEUTICAL COMPOSITION COMPRISING LIDOCAINE AND MELATONIN Sep 27, 2021 Abandoned
Array ( [id] => 17342081 [patent_doc_number] => 20220008412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/449196 [patent_app_country] => US [patent_app_date] => 2021-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17449196 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/449196
Ketamine or dextromethorphan formulations and methods of use Sep 27, 2021 Issued
Array ( [id] => 17503304 [patent_doc_number] => 20220096406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHODS OF TREATING NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION [patent_app_type] => utility [patent_app_number] => 17/477886 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17477886 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/477886
METHODS OF TREATING NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION Sep 16, 2021 Abandoned
Array ( [id] => 18108107 [patent_doc_number] => 20230000987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/467976 [patent_app_country] => US [patent_app_date] => 2021-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17467976 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/467976
Formulations and uses thereof Sep 6, 2021 Issued
Array ( [id] => 17297945 [patent_doc_number] => 20210393784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => INJECTABLE CANNABINOID FORMULATIONS FOR TREATING PAIN [patent_app_type] => utility [patent_app_number] => 17/466087 [patent_app_country] => US [patent_app_date] => 2021-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466087 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/466087
INJECTABLE CANNABINOID FORMULATIONS FOR TREATING PAIN Sep 2, 2021 Abandoned
Array ( [id] => 18690891 [patent_doc_number] => 20230321053 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES [patent_app_type] => utility [patent_app_number] => 18/040508 [patent_app_country] => US [patent_app_date] => 2021-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040508 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/040508
(1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES Aug 19, 2021 Pending
Array ( [id] => 17272853 [patent_doc_number] => 20210379051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS [patent_app_type] => utility [patent_app_number] => 17/400194 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41960 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400194 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/400194
Methods for the treatment of abnormal involuntary movement disorders Aug 11, 2021 Issued
Array ( [id] => 17458658 [patent_doc_number] => 20220071962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => COMPOSITIONS AND METHODS FOR PROVIDING HEALTH BENEFITS IN AN ANIMAL [patent_app_type] => utility [patent_app_number] => 17/398499 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17398499 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/398499
Compositions and methods for providing health benefits in an animal Aug 9, 2021 Issued
Array ( [id] => 18938120 [patent_doc_number] => 20240033259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH BETA CORONAVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/019959 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7335 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019959 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/019959
COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASE ASSOCIATED WITH BETA CORONAVIRUS INFECTION Aug 5, 2021 Pending
Array ( [id] => 18509297 [patent_doc_number] => 20230225368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => INSECT LIFE CYCLE INTERRUPTION AGENT(LCIA) FORMULATIONS AND THEIR MANUFACTURE AND USE [patent_app_type] => utility [patent_app_number] => 18/022042 [patent_app_country] => US [patent_app_date] => 2021-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18022042 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/022042
Insect life cycle interruption agent(LCIA) formulations and their manufacture and use Aug 1, 2021 Issued
Array ( [id] => 18938133 [patent_doc_number] => 20240033272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS [patent_app_type] => utility [patent_app_number] => 18/005838 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005838 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/005838
USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS Jul 14, 2021 Abandoned
Array ( [id] => 20492617 [patent_doc_number] => 12534479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Triazine compound and composition and use thereof [patent_app_type] => utility [patent_app_number] => 18/015381 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22040 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015381 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/015381
Triazine compound and composition and use thereof Jul 8, 2021 Issued
Array ( [id] => 17214402 [patent_doc_number] => 20210347739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => INHIBITION OF OLIG2 ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/367099 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367099 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/367099
Inhibition of Olig2 activity Jul 1, 2021 Issued
Array ( [id] => 17618400 [patent_doc_number] => 11337423 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-05-24 [patent_title] => None [patent_app_type] => utility [patent_app_number] => 17/363682 [patent_app_country] => US [patent_app_date] => 2021-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3808 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17363682 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/363682
None Jun 29, 2021 Issued
Array ( [id] => 18509906 [patent_doc_number] => 20230225992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => LIQUID DISPERSIBLE CURCUMINOID COMPOSITIONS AND METHODS OF IMPROVING COGNITIVE FUNCTION [patent_app_type] => utility [patent_app_number] => 18/012382 [patent_app_country] => US [patent_app_date] => 2021-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012382 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/012382
Liquid dispersible curcuminoid compositions and methods of improving cognitive function Jun 26, 2021 Issued
Array ( [id] => 17140083 [patent_doc_number] => 20210308094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => CESSATION OF ANTI-DEPRESSANT MEDICATION [patent_app_type] => utility [patent_app_number] => 17/351590 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3206 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351590 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/351590
CESSATION OF ANTI-DEPRESSANT MEDICATION Jun 17, 2021 Abandoned
Array ( [id] => 18522895 [patent_doc_number] => 20230233544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => T-TYPE CALCIUM CHANNEL ENHANCER FOR TREATING TAF1 ASSOCIATED NEUROLOGICAL DEFECTS [patent_app_type] => utility [patent_app_number] => 18/001519 [patent_app_country] => US [patent_app_date] => 2021-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001519 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/001519
T-TYPE CALCIUM CHANNEL ENHANCER FOR TREATING TAF1 ASSOCIATED NEUROLOGICAL DEFECTS Jun 10, 2021 Pending
Array ( [id] => 18597147 [patent_doc_number] => 20230271939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/001317 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001317 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/001317
4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS Jun 8, 2021 Pending
Array ( [id] => 18075823 [patent_doc_number] => 20220401435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS [patent_app_type] => utility [patent_app_number] => 17/334872 [patent_app_country] => US [patent_app_date] => 2021-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44558 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 254 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17334872 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/334872
MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS May 30, 2021 Pending
Array ( [id] => 18466871 [patent_doc_number] => 20230201151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => FORMULATIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME, ASTHMA, OR ALLERGIC RHINITIS [patent_app_type] => utility [patent_app_number] => 18/000177 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18000177 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/000177
FORMULATIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME, ASTHMA, OR ALLERGIC RHINITIS May 27, 2021 Pending
Menu